-
公开(公告)号：US09133215B2
公开(公告)日：2015-09-15
申请号：US14156144
申请日：2014-01-15
Applicant: PFIZER INC.
Inventor： Simon Bailey , Benjamin Joseph Burke , Michael Raymond Collins , Jingrong Jean Cui , Judith Gail Deal , Robert Louis Hoffman , Qinhua Huang , Ted William Johnson , Robert Steven Kania , John Charles Kath , Phuong Thi Quy Le , Michele Ann McTigue , Cynthia Louise Palmer , Paul Francis Richardson , Neal William Sach
IPC: C07D273/02 , C07D413/04 , C07D413/14 , C07D491/08 , C07D491/18 , C07D498/08 , C07D498/18 , C07D498/22 , C07D513/18
CPC classification number: C07D498/08 , C07D273/02 , C07D413/04 , C07D413/14 , C07D491/08 , C07D491/18 , C07D498/18 , C07D498/22 , C07D513/18
Abstract: The invention relates to compounds of formula (Φ) as further defined herein and to the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to the uses thereof. The compounds and salts of the present invention inhibit anaplastic lymphoma kinase (ALK) and/or EML4-ALK and are useful for treating or ameliorating abnormal cell proliferative disorders, such as cancer.
Abstract translation: 本发明涉及本文进一步定义的式（Φ）化合物及其药学上可接受的盐，涉及包含这些化合物和盐的药物组合物及其用途。 本发明的化合物和盐抑制间变性淋巴瘤激酶（ALK）和/或EML4-ALK，并且可用于治疗或改善异常细胞增殖性疾病如癌症。
-
公开(公告)号：US20130252961A1
公开(公告)日：2013-09-26
申请号：US13786106
申请日：2013-03-05
Applicant: PFIZER INC.
Inventor： Simon BAILEY , Benjamin Joseph Burke , Michael Raymond Collins , Jingrong Jean Cui , Judith Gail Deal , Robert Louis Hoffman , Qinhua Huang , Ted William Johnson , Robert Steven Kania , John Charles Kath , Phuong Thi Quy Le , Michele Ann McTigue , Cynthia Louise Palmer , Paul Francis Richardson , Neal William Sach
IPC: C07D498/08 , C07D513/18 , C07D498/22 , C07D498/18 , C07D491/18
CPC classification number: C07D498/08 , C07D273/02 , C07D413/04 , C07D413/14 , C07D491/08 , C07D491/18 , C07D498/18 , C07D498/22 , C07D513/18
Abstract: The invention relates to compounds of formula (Φ) as further defined herein and to the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to the uses thereof. The compounds and salts of the present invention inhibit anaplastic lymphoma kinase (ALK) and/or EML4-ALK and are useful for treating or ameliorating abnormal cell proliferative disorders, such as cancer.
Abstract translation: 本发明涉及本文进一步定义的式（Phi）化合物及其药学上可接受的盐，涉及包含这些化合物和盐的药物组合物及其用途。 本发明的化合物和盐抑制间变性淋巴瘤激酶（ALK）和/或EML4-ALK，并且可用于治疗或改善异常细胞增殖性疾病如癌症。
-
公开(公告)号：US20240197703A1
公开(公告)日：2024-06-20
申请号：US18144737
申请日：2023-05-08
Applicant: PFIZER INC.
Inventor： Joyann Barber , Sujin Cho-Schultz , Matthew L. Del Bel , Rebecca Anne Gallego , Mingying He , Mehran Jalaie , Robert Steven Kania , Michele Ann McTigue , Sajiv Krishnan Nair , Anne-Marie Dechert Schmitt , Jamison Bryce Tuttle , Dahui Zhou , Ru Zhou
IPC: A61K31/444 , A61K45/06 , C07D471/04 , C07D519/00
CPC classification number: A61K31/444 , A61K45/06 , C07D471/04 , C07D519/00
Abstract: This invention relates to compounds of general Formula I
and pharmaceutically acceptable salts thereof, in which R1, R2, R3a, R3b, and R4 are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.-
公开(公告)号：US20220017548A1
公开(公告)日：2022-01-20
申请号：US17365213
申请日：2021-07-01
Applicant: Pfizer Inc.
Inventor： Robert Steven Kania , Padmavani Bezawada , Emma Louise Hawking , Rohit Jaini , Samir Kulkarni , Matthew Nathan O'Brien Laramy , Jonathan Richard Lillis , Suman Luthra , Dafydd Rhys Owen , Klimentina Dimitrova Pencheva , Martin Youngjin Pettersson , Anil Mahadeo Rane , Matthew Forrest Sammons , Bradley Paul Sullivan , Andrew John Thiel , Martyn David Ticehurst , Jamison Bryce Tuttle , Robert Louis Hoffman
Abstract: The invention relates to compounds of formula I wherein R1, R2 and - - - - - are as defined herein, pharmaceutical compositions comprising the compounds and methods of treating COVID-19 in a patient by administering therapeutically effective amounts of the compounds and methods of inhibiting or preventing replication of SARS-CoV-2 with the compounds.
-
公开(公告)号：US10125130B2
公开(公告)日：2018-11-13
申请号：US15826027
申请日：2017-11-29
Applicant: PFIZER INC.
Inventor： Aaron Craig Burns , Michael Raymond Collins , Samantha Elizabeth Greasley , Robert Louis Hoffman , Peter Qinhua Huang , Robert Steven Kania , Pei-Pei Kung , Maria Angelica Linton , Lakshmi Sourirajan Narasimhan , Paul Francis Richardson , Daniel Tyler Richter , Graham Smith
IPC: C07D417/14 , C07D417/08 , A61K31/427 , A61K31/4439 , A61K31/444 , A61K31/501 , A61K31/506 , A61K45/06 , C07D277/46 , C07D401/14
Abstract: The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein A, L, D, R1-R15, w, x, y, and z are defined herein. The novel cycloalkyl-linked diheterocycle derivatives that are useful in the treatment of abnormal cell growth, such as cancer, in mammals. The present invention also relates to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.
-
Patent Agency Ranking
公开(公告)号：US08680111B2
公开(公告)日：2014-03-25
申请号：US13786106
申请日：2013-03-05
Applicant: Pfizer Inc.
Inventor： Simon Bailey , Benjamin Joseph Burke , Michael Raymond Collins , Jingrong Jean Cui , Judith Gail Deal , Robert Louis Hoffman , Qinhua Huang , Ted William Johnson , Robert Steven Kania , John Charles Kath , Phuong Thi Quy Le , Michele Ann McTigue , Cynthia Louise Palmer , Paul Francis Richardson , Neal William Sach
IPC: A01N43/42 , A61K31/44 , A01N43/02 , A61K31/335 , C07D471/00 , C07D491/00 , C07D498/00 , C07D513/00 , C07D515/00 , C07D313/00
CPC classification number: C07D498/08 , C07D273/02 , C07D413/04 , C07D413/14 , C07D491/08 , C07D491/18 , C07D498/18 , C07D498/22 , C07D513/18
Abstract: The invention relates to compounds of formula (Φ) as further defined herein and to the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to the uses thereof. The compounds and salts of the present invention inhibit anaplastic lymphoma kinase (ALK) and/or EML4-ALK and are useful for treating or ameliorating abnormal cell proliferative disorders, such as cancer.
Abstract translation: 本发明涉及本文进一步定义的式（Φ）化合物及其药学上可接受的盐，涉及包含这些化合物和盐的药物组合物及其用途。 本发明的化合物和盐抑制间变性淋巴瘤激酶（ALK）和/或EML4-ALK，并且可用于治疗或改善异常细胞增殖性疾病如癌症。
-
公开(公告)号：US11926642B2
公开(公告)日：2024-03-12
申请号：US17365213
申请日：2021-07-01
Applicant: Pfizer Inc.
Inventor： Robert Steven Kania , Padmavani Bezawada , Emma Louise Hawking , Rohit Jaini , Samir Kulkarni , Matthew Nathan O'Brien Laramy , Jonathan Richard Lillis , Suman Luthra , Dafydd Rhys Owen , Klimentina Dimitrova Pencheva , Anil Mahadeo Rane , Matthew Forrest Sammons , Bradley Paul Sullivan , Andrew John Thiel , Martyn David Ticehurst , Jamison Bryce Tuttle , Robert Louis Hoffman
CPC classification number: C07F9/5728 , A61P31/14 , C07B2200/13
Abstract: The invention relates to compounds of formula I
wherein R1, R2 and - - - - - are as defined herein, pharmaceutical compositions comprising the compounds and methods of treating COVID-19 in a patient by administering therapeutically effective amounts of the compounds and methods of inhibiting or preventing replication of SARS-CoV-2 with the compounds.-
公开(公告)号：US11684616B2
公开(公告)日：2023-06-27
申请号：US17246551
申请日：2021-04-30
Applicant: PFIZER INC.
Inventor： Joyann Barber , Sujin Cho-Schultz , Matthew L. Del Bel , Rebecca Anne Gallego , Mingying He , Mehran Jalaie , Robert Steven Kania , Michele Ann McTigue , Sajiv Krishnan Nair , Anne-Marie Dechert Schmitt , Jamison Bryce Tuttle , Dahui Zhou , Ru Zhou
IPC: C07D471/04 , C07D519/00 , A61K31/444 , A61K45/06
CPC classification number: A61K31/444 , A61K45/06 , C07D471/04 , C07D519/00
Abstract: This invention relates to compounds of general Formula I
and pharmaceutically acceptable salts thereof, in which R1, R2, R3a, R3b, and R4 are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.-
公开(公告)号：US11220494B2
公开(公告)日：2022-01-11
申请号：US16942209
申请日：2020-07-29
Applicant: Pfizer Inc.
Inventor： Ping Chen , Sujin Cho-Schultz , Judith Gail Deal , Gary Michael Gallego , Mehran Jalaie , Robert Steven Kania , Sajiv Krishnan Nair , Sacha Ninkovic , Suvi Tuula Marjukka Orr , Cynthia Louise Palmer
IPC: C07D407/14 , C07D401/14 , C07D487/04 , C07D498/04
Abstract: This invention relates to compounds of Formula (I) or a pharmaceutically acceptable salt thereof, in which R-groups R1 to R23, A, Q, U, V, W, X, Y, Z, n, p and q are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject.
-
公开(公告)号：US10766884B2
公开(公告)日：2020-09-08
申请号：US16391836
申请日：2019-04-23
Applicant: Pfizer Inc.
Inventor： Ping Chen , Sujin Cho-Schultz , Judith Gail Deal , Gary Michael Gallego , Mehran Jalaie , Robert Steven Kania , Sajiv Krishnan Nair , Sacha Ninkovic , Suvi Tuula Marjukka Orr , Cynthia Louise Palmer
IPC: C07D407/14 , C07D401/14 , C07D487/04 , C07D498/04
Abstract: This invention relates to compounds of Formula (I) or a pharmaceutically acceptable salt thereof, in which R-groups R1 to R23, A, Q, U, V, W, X, Y, Z, n, p and q are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject.
-
-
-
-
-
-
-
-
-
Search Results
31
records
(took 0.03 seconds)
